Medical-device giant Boston Scientific ( BSX ) hit a 10-year high in early trading Thursday after it announced a restructuring plan late Wednesday, and received a favorable initiation report from Guggenheim. Boston Scientific didn't release many details, but its 8-K filing said that it furthers the company's plant network optimization strategy, "which is intended to simplify the Company's manufacturing plant structure by transferring certain production lines among facilities." It expects no overall reduction in head count, but said it will reduce annual operation expenses by $115 million to $150 million by 2020. RBC Capital Markets analyst Glenn Novarro wrote that the move isn't surprising since Boston Scientific has committed to margin expansion. Operating margin was about 22% last year, but the company is targeting 25% in 2017 and 28% to 30% long-term.